2022
DOI: 10.3390/ijms232112932
|View full text |Cite
|
Sign up to set email alerts
|

Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer

Abstract: Plasma cell-free DNA (cfDNA) sequencing data have been widely studied for early diagnosis and treatment response or recurrence monitoring of cancers because of the non-invasive benefits. In cancer studies, whole exome sequencing (WES) is mostly used for discovering single nucleotide variants (SNVs), but it also has the potential to detect copy number alterations (CNAs) that are mostly discovered by whole genome sequencing or microarray. In clinical settings where the quantity of the acquired blood from the pat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…The 10th International Workshop for Waldenström's macroglobulinemia (IWWM-10) recommended BTK inhibitors alone or in combination with rituximab as first-line treatment options for WM patients (4). With the advance of precision medicine, circulating tumor DNA (ctDNA) extracted from body fluids, including blood, cerebrospinal fluid, pleural effusion, and ascites, has been used for cancer genomic profiling (5)(6)(7)(8). Resistance to BTK inhibitors secondary to histological transformation in WM is rare.…”
Section: Introductionmentioning
confidence: 99%
“…The 10th International Workshop for Waldenström's macroglobulinemia (IWWM-10) recommended BTK inhibitors alone or in combination with rituximab as first-line treatment options for WM patients (4). With the advance of precision medicine, circulating tumor DNA (ctDNA) extracted from body fluids, including blood, cerebrospinal fluid, pleural effusion, and ascites, has been used for cancer genomic profiling (5)(6)(7)(8). Resistance to BTK inhibitors secondary to histological transformation in WM is rare.…”
Section: Introductionmentioning
confidence: 99%